Truist Securities upgraded Pacira Pharmaceuticals (NASDAQ:PCRX) stock rating from Hold to Buy, significantly raising the price target to $25.00 from the previous $8.00. The stock, currently trading at ...
Fintel on MSN17h
Truist Securities Initiates Coverage of Larimar Therapeutics (LRMR) with Buy RecommendationFintel reports that on January 29, 2025, Truist Securities initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a ...
On Wednesday, Truist Securities provided insights into the AI enterprise software market, highlighting several companies poised to benefit from the ongoing investments in generative AI (GenAI).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback